The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study

BACKGROUND: High treatment prices of new cancer drugs are a global public health challenge to patients and healthcare systems. Policymakers in the US and Europe are debating reforms to drug pricing. The objective of this study was to assess whether drug efficacy or epidemiological characteristics (p...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra-Burriel, Miquel, Perényi, Gellért, Laube, Yannic, Mitchell, Aaron P., Vokinger, Kerstin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371812/
https://www.ncbi.nlm.nih.gov/pubmed/37521033
http://dx.doi.org/10.1016/j.eclinm.2023.102087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371812/
https://www.ncbi.nlm.nih.gov/pubmed/37521033
http://dx.doi.org/10.1016/j.eclinm.2023.102087

Ejemplares similares